Clinical Trials Browser

Myeloproliferative Disorders × ruxolitinib × 90 days × Clear all

NCT06034002 2026-04-17

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Phase 1 Recruiting

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04562389 2026-04-09

SENTRY

Phase 3 Active not recruiting

Myeloproliferative Disorders, Primary Myelofibrosis

NCT05088356 2026-04-08

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04279847 2026-04-01

LIMBER

Phase 1 Active not recruiting

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

NCT01787487 2026-03-31

Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Phase 2 Completed

Myeloproliferative Disorders, Polycythemia Vera, Primary Myelofibrosis

NCT05936359 2026-03-24

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Phase 1 Recruiting

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis